Research

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

VUMC faculty members attending the meeting of the American Society for Clinical Investigation included, from left, Wesley Ely, MD, MPH, Patrick Hu, MD, PhD, Lorraine Ware, MD, Kimryn Rathmell, MD, PhD, Consuelo Wilkins, MD, MSCI, Christopher Williams, MD, PhD, Lori Jordan, MD, PhD, Natasha Halasa, MD, MPH, ASCI Council Member Julie Bastarache, MD, Eric Tkaczyk, MD, PhD, and James Crowe Jr., MD.

VUMC a national leader in physician-scientist training

Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.

When science spills onto social media

Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.

Aviv Regev, PhD, recipient of the 2021 Vanderbilt Prize in Biomedical Science, gestures to an illustration during her Vanderbilt Prize Discovery Lecture on April 14.

Regev’s Discovery Lecture

Aviv Regev, PhD, recipient of the 2021 Vanderbilt Prize in Biomedical Science, gave her Vanderbilt Prize Discovery Lecture on April 14.

Youthful healing for burn wounds

Topical treatment of burns with an immunosuppressive drug counteracted the negative effects of aging on wound healing, Vanderbilt researchers have discovered.

1 40 41 42 43 44 126